Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
| Autor: | Masanori Abe, Akiko Toshimori, Yoshifumi Suga, Nobuaki Azemoto, Tomoe Kawamura, Hiroka Yamago, Kojiro Michitaka, Masashi Hirooka, Tomonari Okudaira, Hideki Miyata, Hiromasa Nakahara, Tomoyuki Ninomiya, Yasunao Miyamoto, Hideki Kawasaki, Yoshihiro Ishimaru, Toshihiko Aibiki, Yoichi Hiasa, Atsushi Hiraoka, Bunzo Matsuura |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology Sorafenib Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Kaplan-Meier Estimate Fucose metabolism Gastroenterology Refractory Predictive Value of Tests Internal medicine Biomarkers Tumor medicine Carcinoma Humans Treatment Failure AFP-L3 Chemoembolization Therapeutic Protein Precursors Transcatheter arterial chemoembolization Aged Fucose Tumor marker Aged 80 and over business.industry Liver Neoplasms General Medicine Middle Aged Prognosis medicine.disease digestive system diseases Treatment Outcome Hepatocellular carcinoma Female Prothrombin alpha-Fetoproteins Neoplasm Recurrence Local business Biomarkers medicine.drug |
| Zdroj: | Oncology. 89:167-174 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Background/Aim: We examined tumor marker levels to assess in more detail transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). Materials and Methods: We enrolled patients treated from 2000 to 2011 for HCC beyond the Milan criteria who had good hepatic reserve function (Child-Pugh A) and no portal vein thrombosis or metastases (n = 154). The modified criteria for being TACE-refractory according to the Liver Cancer Study Group of Japan (m-LCSGJ), from which the tumor marker item was excluded, and the Assessment for Retreatment with TACE (ART) score were used for determining whether the HCC was TACE refractory. α-Fetoprotein ≥100 ng/ml, fucosylated α-fetoprotein ≥10%, and des-gamma-carboxy prothrombin ≥100 mAU/ml were used to define whether tumor markers were positive. We added up the number of positive tumor markers as a prognostic score to assess in more detail the evaluation of TACE-refractory HCC. Results: In order to divide the patients into a refractory and nonrefractory group, the m-LCSGJ criteria [mean survival time (MST) 27.1 vs. 49.9 months; p < 0.001] were superior to the ART score (MST 22.0 vs. 35.1 months; p = 0.051). In the refractory group according to the m-LCSGJ criteria, the patients with a low score of positive tumor markers (Conclusion: Patients being nonrefractory according to the m-LCSGJ criteria had a better response, and using the number of tumor markers (≥2) is an easy method for predicting the response to TACE and for a more detailed evaluation of TACE-refractory HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|